Merck Sees &#39;05 Earnings Decline, Stock Up
685306
Merck &amp; Co. Inc. (MRK.N: Quote, Profile, Research) , reeling from the recent withdrawal of its Vioxx arthritis drug, on Wednesday said 2005 earnings will decline to
349051
Shares of drugmaker Merck & Co. Inc.  traded 1.52 percent higher on volume of more than 61,000 shares in pre-market dealings on Friday, a day after the stock plunged to an eight-year low after the company withdrew its arthritis drug Vioxx.
724445
Wall Street closed out a dismal third quarter with a mixed performance Thursday after Merck &amp; Co. said it would be forced to remove its best-selling Vioxx arthritis drug from the market.
474839
The Toronto stock market posted a small gain today, pushed higher by the gold sector, but drug company Merck &amp; Co. took the Dow Jones industrial average into the red after taking its arthritis drug Vioxx off the market.
69797
Merck & Co.  on Wednesday stood  by its forecast of flat earnings for 2006 and projected  slightly higher 2007 results, in line with Wall Street  expectations, as the drugmaker grapples with generic  competition for a number of its medicines.
297628
Merck & Co. MRK.N on Thursday  reported a 28 percent drop in quarterly profit and said 2004  earnings will fall as much as 11 percent due to last month's  recall of its Vioxx arthritis drug.
695075
The U.S. Dow Jones Industrial average declined on Thursday after drug maker Merck & Co. recalled its widely sold Vioxx painkiller and its stock sunk 27 percent.
186104
The withdrawal of painkiller Vioxx means Merck &amp; Co. will miss the already diminished expectations of Wall Street analysts for 2005, the drug maker said yesterday.
628191
Merck & Co. Inc. MRK.N, whose  earnings are being hurt by the withdrawal of its arthritis drug  Vioxx, said on Tuesday it has increased the number of jobs to  be cut by year-end to 5,100 from 4,400.
501273
Merck & Co. on Wednesday maintained its forecast of flat earnings for 2006 and slightly higher 2007 results as the drugmaker grapples with generic competition, sending its shares down about 1.4 percent.
12128
The drug maker Merck & Company forecast flat earnings for 2006 and slightly higher 2007 results as it grapples with generic competition.
258893
Shares of Merck & Co.  fell about 3 percent before the bell on Tuesday after the drug maker said federal authorities are investigating circumstances surrounding its withdrawal of pain-relief medicine Vioxx.
77029
Now that Merck &amp; Co.&#39;s $2.5 billion annual revenues from anti-inflammatory COX-2 inhibitor VIOXXÂ® are history, the next question is what happens to the even greater amount of money ($3.
627734
Merck &amp; Co. Inc. (MRK.N: Quote, Profile, Research) , whose shares have tumbled since the withdrawal of its blockbuster arthritis drug Vioxx, said on Monday it has adopted a severance benefits
764330
U.S. stock futures pointed to a  slightly lower open on Tuesday as investors take a step back  after last week's three-day rally, with shares of drug maker  Merck & Co. MRK.N under pressure as regulators step up  investigations into the company's withdrawal of its pain  reliever, Vioxx.
462841
Wall Street&#39;s earnings growth, fuelled by two years of robust trading gains, is showing signs that it might taper off in coming quarters as a sluggish stockmarket and a less favourable trading environment take a toll on profits.
473820
As far as stock hits go, this ranks up there as one of the worst. Merck &amp; Co. lost more than $26.6 billion in value yesterday - yes, that&#39;s billion with ab - after the pharmaceutical giant